Bromide

Bromide

SCHEMBL4448055

Br.Br.N=C(N)SCCc1ccccc1Sc1ccccc1CSC(=N)N

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 6/20 0.51
IDO1 P14902 8/20 0.51
HTT P42858 4/20 0.51
LMNA P02545 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
TAAR1 Q96RJ0 2/20 0.51
HPGD P15428 1/20 0.49
BLM P54132 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
CYP2D6 P10635 2/20 0.46
NOS3 P29474 2/20 0.46
NOS2 P35228 2/20 0.46
NPC1 O15118 1/20 0.46
CYP3A4 P08684 1/20 0.46
RAB9A P51151 1/20 0.46
HIF1A Q16665 1/20 0.46
SLC11A2 P49281 2/20 0.44
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3683034 0.98 NOS1 (0.53) NOS1IDO1HTTLMNASMN1; SMN2
SCHEMBL14068683 0.92 NOS1 (0.59) NOS1IDO1HTTLMNASMN1; SMN2
Bromide SCHEMBL4442782 0.91 IDO1 (0.61) NOS1IDO1HTTLMNASMN1; SMN2
SCHEMBL3684271 0.89 IDO1 (0.62) NOS1IDO1HTTLMNASMN1; SMN2
Bromide SCHEMBL4446847 0.88 NOS1 (0.43) NOS1IDO1HTTLMNASMN1; SMN2
SCHEMBL3693561 0.86 NOS1 (0.44) NOS1IDO1HTTLMNASMN1; SMN2
Bromide SCHEMBL22263123 0.85 NOS1 (0.59) NOS1IDO1HTTLMNASMN1; SMN2
SCHEMBL22275669 0.84 NOS1 (0.61) NOS1IDO1HTTLMNASMN1; SMN2
Bromide SCHEMBL4440550 0.81 IDO1 (0.50) NOS1IDO1HTTLMNASMN1; SMN2
SCHEMBL3685349 0.79 IDO1 (0.51) NOS1IDO1HTTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061754-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2009-05-27 EP disclosed
WO-2008115999-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 WO disclosed
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS FECH, SLC10A1, SLC40A1 NOS1 1119/4885IDO1 269/4885HTT 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.